Trade ARWR

Arrowhead Research Corp

-

00:00:00

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company’s products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Read more...

1D Change

4.925%

Why BlackBull Markets?

26k+

Tradable Assets

1:500

Leverage up to

Regulated

Multi-Regulated

24/7

Customer Support

$0

No Minimum Deposit

TRADING CONDITIONS

ARWR
TRADING CONDITIONS

Digits

3

Point

0.001

Spread

 
floating

Contract Size

1

Volume Min

1

Volume Max

10,000

Volume Step

1

Swap Long (Points)

 
-9.160

Swap Short (Points)

-5.300
Available on
MT5, TV, cTrader
Last update at June 17, 20:08 GMT+3
*Data Source: MT5 Server Prime Account Pricing

Margin Calculator

Calculation Results

Current Price

25.04

Required Margin

Converted Currency

Required Margin

Account Base Currency

How it works:

Use our margin calculator to determine the funds required to open and maintain positions.

Select your account base currency, an asset pair, the size of your position in lots, and your level of leverage. 


The calculation is carried out as follows:
Required Margin = Trade Size / Leverage * Account Currency Exchange Rate

Profit/Loss Calculator

Calculation Results

PIP Value:

Stop loss in PIPs

Stop loss at :

Take profit in PIPs

Take profit at :

How it works:

Use our profit and loss calculator to determine where to place your take profit and stop loss. 

 

Select your account base currency, an asset pair, the size of your position in lots, choose between a long buy and a short sell, and input a stop loss and take profit value. 


The calculation is carried out as follows:
SL / TP Levels = SL, TP Amount / Pip Value Formula * Exchange Rate

Swaps Calculator

Calculation Results

25.04

How it works:

Use our swaps calculator to determine the interest rate differential between two assets. 

 

Select your account base currency, an asset pair, the size of your position in lots. 


The calculation is carried out as follows:
Swap = (One Point / Exchange Rate) * Trade Size (Lot Size) * Swap Value in Points

Currency Calculator

Calculation Results

Loading...

How it works:

Use our currency calculator to determine the value of one currency against another, based on current exchange rates.

Join Now